Time to Treatment Versus Health Care Utilization in Compression Fractures Treated With Vertebral Augmentation: The Vertebral Augmentation Care Pathways Case Series
- PMID: 40587613
Time to Treatment Versus Health Care Utilization in Compression Fractures Treated With Vertebral Augmentation: The Vertebral Augmentation Care Pathways Case Series
Abstract
Background: There is little data on the economics of the timing of percutaneous vertebral augmentation (PVA) for vertebral compression fractures (VCFs).
Case report: The purpose of this case series is to compare health care utilization (HCU) costs vs the time to treatment (TTT) of the VCF. The BenchMarket Medical VCF Registry (now Talosix) was utilized. Patients receiving acute or intermediate treatment had the greatest pain and function improvement and the lowest HCU costs. Patients receiving delayed treatment had the least improvement and the highest (3-fold) HCU costs. Any TTT delay resulted in higher HCU costs and diminished benefits. The most beneficial PVA outcome and lowest HCU costs were recorded in patients whose PVA was expedited and performed within 3 months from injury.
Conclusions: This series suggests the best pain and function improvement and lowest HCU costs result from efficient, timely PVA.
Keywords: Vertebroplasty; case series; health care economics; health care overutilization; kyphoplasty; osteoporotic fracture; registry.
Conflict of interest statement
NHS has received compensation unrelated to this study, related to royalties (Globus), consulting, research, and teaching (Medtronic). DPB declares the following disclosures: Unrelated to this study, I received compensation from Medtronic related to consultancy, research, and teaching. DPB also declares grants from Benvenue; grants and personal fees from Medtronic, Halyard, Vivex, and Vertiflex; consultancy fees from Dfine, Osseon; othersfrom Lilly, Smith & Nephew, Biomet, Vertiflex, Synthes, and Integral Spine Solutions; and grants from Alphatech Spine, Medical Metrics, Liventa, Vexim, and Mesoblast. Remaining authors certify that he or she, or a member of his or her immediate family, has no commercial association (i.e., consultancies, stock ownership, equity interest, patent/licensing arrangements, etc.) that might pose a conflict of interest in connection with the submitted manuscript.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous